CLNN — Clene Inc.
Is CLNN overbought or oversold? Here is the current MarketMoodz read.
Clene Inc. (CLNN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Consumer Defensive name (Packaged Foods) last closed at $3.66. The rating moved from Overbought to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$3.66
- Last changeMoved from Overbought to Oversold on November 14, 2026
- SectorConsumer Defensive
- IndustryPackaged Foods
See all oversold Consumer Defensive stocks →
AI analysis
Clene Inc. appears to trade like a typical clinical-stage small-cap biotech: valuation and near-term direction are driven primarily by clinical and partnership catalysts and by the supply/demand dynamics of a thinly traded stock. Public information in the packet is limited, so cash runway and near-term financing risk are key unknowns. A risk-on market provides short-term support, but the company remains highly event-driven and volatile; outcomes from trials or business development actions will materially change prospects.
Key factors
- Small-cap biotech profile with outcomes-driven valuation: share moves likely tied to clinical/data catalysts rather than steady revenue streams
- Limited public financial and EDGAR data available in the materials provided, increasing uncertainty around cash runway and near-term funding needs
- Current market tone is risk-on, which supports speculative growth and clinical-stage names in the short term
- Potential upside from positive clinical readouts, partnerships, or licensing deals that could materially de‑risk the business
- Relative illiquidity and low retail/research coverage increases volatility and the potential for outsized intraday moves
- Sector-agnostic investor flows into growth could provide temporary bid support independent of company fundamentals
Risks
- Clinical trial failure or delayed readouts leading to sharp share price declines
- Insufficient cash runway or need for dilutive financing absent near-term revenue or partner deals
- Regulatory setbacks or longer-than-expected approval timelines
- High execution risk typical for clinical-stage therapeutics (manufacturing, enrollment, endpoints)
- Limited analyst coverage and scarce institutional ownership increasing volatility and widening spreads
- Macro shifts (risk-off) could disproportionately depress small-cap biotech equities regardless of company-specific news
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for CLNN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.